Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Quanticate
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Quanticate
-
We're excited to announce our first conference attendance of 2020. Are you going to be in Orlando for the
#SCOPESummit2020? Schedule a meeting with our Vice President Business Development, Ben Payne. He's looking forward to meeting you there.https://hubs.ly/H0mVj2R0Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
There are potential pitfalls with the production of
#SAS Macros! So, how do you make a successful process improvement project. https://hubs.ly/H0mT-z60#Programming#ClinicalTrialHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
[NEW BLOG] The Integrations of studies are important. It's especially important for setting up safety and efficacy profiles of the component of interest that are referred to as ISS and
#ISE. https://hubs.ly/H0mSNBx0#CDISC#ADaMHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Substantial quantities of SAS Code can be difficult to navigate. Just as difficult to debug and manage if poorly planned and laid out. Get clued up on how to handle large
#SAS#Data https://hubs.ly/H0mQKYp0#CodeHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
How to Create Custom or Non-Standard
#CDISC#SDTM Domains https://hubs.ly/H0mQJzl0#ProgrammingHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Response to
#Cancer treatment is not a simple question of whether the subject still has it or not. The efficacy endpoints in#Oncology Studies uses the RECIST method to assess how Solid Tumours change over the course of a study.https://hubs.ly/H0mHj880Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Proc
#SQL tends to divide#SAS#Programmers, who often either love it or hate it. Are there situations that it should always be used? Conversely, have you seen examples of it being used completely inappropriately?Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Analyzing Multiple End Points in
#ClinicalTrials. ** Includes Example of#Bayesian Methodology using Simulated#Data **https://hubs.ly/H0mHm9j0Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The American College of Rhematology (ACR) Criteria is a standard criterion to measure the effectiveness of various
#Medications. ACR response is used to discriminate proven effective#Treatments from Placebo Treatments in a#ClinicalTrial setting.https://hubs.ly/H0mHjqD0Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
How to create portable programs using the
#SAS Macro Language with SAS Learning Post. https://hubs.ly/H0mHkP70#ProgrammingHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
There are several articles stating controversies regarding
#Bayesian inference. What difficulties have you faced in adopting the Bayesian methods?Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Do you know the benefits of Statistical Consultancy in device or
#DrugDevelopment programmes? Statistical Consultants offer advice from Study Design and strategies, to the analysis of Study#Data and informed interpretation of results. https://hubs.ly/H0mH8Z00#ClinicalTrialsHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#ADaM#Datasets is widely used in the submission of#ClinicalTrial information.https://hubs.ly/H0mG-xF0Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Phase I packages can be tailored to the needs of the specific compound and be conducted more efficiently using combination of flexible protocols. There are considerations that need to be made at the planning stage. https://hubs.ly/H0mH5Rm0
#DrugDevelopmentHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In an industry which is under increasing pressure to achieve ‘more with less’, and in an environment where the opposite is true. Adaptive
#ClinicalTrials are generating more interest than ever before. https://hubs.ly/H0mFk7Y0#PharmaceuticalsHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
There are different ways to improve efficiency in
#DrugDevelopment.#InterimAnalyses is one of those ways. The#Bayesian Framework is highly appropriate for this.https://hubs.ly/H0mF3gW0Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
What are the regulatory reasons of using Tipping Point Analysis in
#MultipleImputation for#Binary Missing#Data, and it's impact?https://hubs.ly/H0mF5jl0Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Want to achieve efficiency in
#ClinicalProgramming#Data? Explore balanced perspectives over narrow perspectives and how overall efficiencies and distinct efficiencies need to be separated.https://hubs.ly/H0mF5Zy0Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Food Ingredient and
#Nutraceutical manufacturers are increasingly looking to market their products by substantiating their unique#HealthBenefits. https://hubs.ly/H0mDmnf0#TrialDesignHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Quanticate proslijedio/la je Tweet
We recently sat down with industry expert Deepu Joseph of
@Quanticate to define#eSource, its positive impact on#clinicaltrialdesign and teams, and how it facilitates#patientcentricity. Read the blog to learn more about the benefits of#eSourceadoption! http://bit.ly/2RrhJkR pic.twitter.com/6H4IXHV5qN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.